Author: Abhay Panchal

An aging U.S. population with a preference for growing older at home — and a fiscally challenging health care financing outlook — are setting the demographic and financial table for the shift of medical care to peoples’ homes discussed in The State of Health at Home Models: Key Considerations and Opportunities, published by the American Medical Association (AMA).

Read More

Endoscopists with varying experience had high levels of procedural success and reported high levels of satisfaction performing endoscopic retrograde cholangiopancreatography using a single-use duodenoscope, including in a significant number of high-complexity cases, according to a multicenter, global prospective case series presented at Digestive Disease Week 2023. Although a disposable duodenoscope virtually eliminates the problem of scope contamination, other questions about these devices remained. Would endoscopists be comfortable with the disposable designs, and would they find that they performed the same?

Read More

Abstract: The presentation of eosinophilic esophagitis (EoE) is heterogeneous with varied clinical, endoscopic, and histologic features impacting the severity of the condition. Until recently, however, and in contrast with many other conditions, there has been no standardized way to measure disease severity in EoE. A clinically applicable method for assessing severity in routine practice has been recognized as necessary to standardize assessment and management of EoE. Therefore, the American Gastroenterological Association has sponsored a consensus conference to determine elements of severity in EoE and develop the first tool to measure severity. This article presents details of this severity metric, which…

Read More

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated. That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug…

Read More

Three primary stakeholders may play a role in protecting patients from the infection risk associated with reusable gastroscopes: healthcare providers, endoscope manufacturers and the U.S. Food and Drug Administration. Dr. Lawrence Muscarella, a national authority on the causes and prevention of healthcare-associated infections, offered advice to those stakeholders on the Transmission Control podcast in the third episode of a three-part series on gastroscope safety signals.

Read More

A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk of severe stomach problems. The lawsuit seeks “very significant” but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Fla.-based firm Morgan & Morgan.

Read More

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted the growing recognition that diet, specifically tailored nutrition interventions, can play a crucial role in the management of several gastrointestinal disorders. “We all know, especially in [inflammatory bowel disease], the re-emerging of diet as an important factor in terms of how to manage patients, and I think that recognition has played out in other parts of GI as well,” Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at the Mayo Clinic told Healio.

Read More

Some clinicians say it’s “confusing” and “ridiculous” to change the name and diagnostic criteria of an established liver disease, while others bemoan the seemingly political reasons why it happened. Yet recently, 236 panelists from 56 countries decided that the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) rely on “exclusionary confounder terms and the use of potentially stigmatizing language.” In a report published June 24 in the Journal of Hepatology, the panelists, members of the NAFLD Nomenclature Consensus Group, determined that steatotic liver disease (SLD) would be used as an “overarching term to encompass the various etiologies of…

Read More